Allarity Therapeutics, Inc. Liabilities, Fair Value Adjustment
Allarity Therapeutics, Inc. (ALLR) reported Liabilities, Fair Value Adjustment of $4.94 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2023-11-14
- Allarity Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2023-09-30 was $4.94M, a 246750.00% increase year-over-year.
- Allarity Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2023-06-30 was $1.94M, a 122.08% increase year-over-year.
- Allarity Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2023-03-31 was $309.00K, a 97.54% decline year-over-year.
- Allarity Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2022-12-31 was $3.68M, a 890.05% increase year-over-year.
- Allarity Therapeutics, Inc. liabilities, fair value adjustment for fiscal 2022 was $17.13M, a 720.56% increase from fiscal 2021.
- Allarity Therapeutics, Inc. liabilities, fair value adjustment for fiscal 2021 was $2.09M, a 2.06% decline from fiscal 2020.
- Allarity Therapeutics, Inc. liabilities, fair value adjustment for fiscal 2020 was $2.13M.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 3 month as first filed | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 9 month as first filed | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|---|---|
| 2023-09-30 | $4.94M 10-Q · filed 2023-11-14 | $6.88M derived: sum of 2 quarters · filed 2023-11-14 | $7.19M 10-Q · filed 2023-11-14 | $10.87M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2023-06-30 | $1.94M 10-Q · filed 2023-08-14 | $2.25M 10-Q · filed 2023-08-14 | $5.93M derived: sum of 3 quarters · filed 2023-08-14 | $5.93M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2023-03-31 | $309.00K 10-Q · filed 2023-05-11 | $3.99M derived: sum of 2 quarters · filed 2023-05-11 | $3.99M derived: sum of 3 quarters · filed 2023-11-14 | $4.87M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $3.69M derived: sum of 2 quarters · filed 2023-11-14 | $4.56M derived: sum of 3 quarters · filed 2023-11-14 | $17.13M 10-K · filed 2023-03-13 | ||
| 2022-09-30 | $2.00K 10-Q · filed 2023-11-14 | $876.00K derived: sum of 2 quarters · filed 2023-11-14 | $13.44M 10-Q · filed 2023-11-14 | $13.81M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $874.00K 10-Q · filed 2023-08-14 | $13.44M 10-Q · filed 2023-08-14 | $13.81M derived: sum of 3 quarters · filed 2023-08-14 | $15.60M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $12.57M 10-Q · filed 2023-05-11 | $12.94M derived: sum of 2 quarters · filed 2023-05-11 | $14.72M derived: sum of 3 quarters · filed 2023-05-11 | $14.70M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $2.16M derived: sum of 2 quarters · filed 2023-03-13 | $2.13M derived: sum of 3 quarters · filed 2023-03-13 | $2.09M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | $1.78M 10-Q · filed 2022-11-14 | -$4.52M 10-Q · filed 2021-11-23 | $1.76M derived: sum of 2 quarters · filed 2022-11-14 | $1.72M 10-Q · filed 2022-11-14 | -$4.55M 10-Q · filed 2021-11-23 | $2.98M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$25.00K 10-Q · filed 2022-10-07 | $20.00K 10-Q · filed 2022-10-07 | $1.19M derived: sum of 3 quarters · filed 2022-10-07 | $1.09M derived: sum of 4 quarters · filed 2022-10-07 | ||
| 2021-03-31 | $45.00K 10-Q · filed 2022-05-27 | $1.22M derived: sum of 2 quarters · filed 2022-05-27 | $1.11M derived: sum of 3 quarters · filed 2022-05-27 | |||
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | $1.07M derived: sum of 2 quarters · filed 2022-05-17 | $2.13M 10-K · filed 2022-05-17 | |||
| 2020-09-30 | -$104.00K 10-Q/A · filed 2022-05-17 | $104.00K 10-Q · filed 2021-11-23 | $957.00K 10-Q/A · filed 2022-05-17 | -$957.00K 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |